BEAM logo

Beam Therapeutics Inc.

BEAM
Healthcare|Biotechnology|US
$26.41
+0.54 (+2.09%)
Tangible Book / Share
$9.10
Cash / Share
$9.97
Next Earnings Report
Feb 23, 2027
EPS est. -$1.29 · Revenue est. $5.4M
Financing Filings (last 12 months)
0
No shelf registrations or offering prospectuses filed.

Upcoming Data Readouts (8)

Dec 2026
Est. completion
Sickle Cell Trait
Achieving Understanding of the Natural History of Sickle Cell Trait (AUNT)
Dec 2026
Est. completion
P1P2Lymphoblastic Lymphoma
A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)
Dec 2027
Est. completion
P1P2Glycogen Storage Disease Type Ia
A Phase 1/2, Dose-Exploration Study to Evaluate the Safety and Efficacy of BEAM-301 in Patients With Glycogen Storage Disease Type Ia (GSDIa)
Feb 2028
Est. completion
P1P2Sickle Cell Disease
BEACON: A Study Evaluating the Safety and Efficacy of BEAM-101 in Patients With Severe Sickle Cell Disease
May 2028
Est. completion
P1P2Alpha 1-Antitrypsin Deficiency
A Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With Alpha-1 Antitrypsin Deficiency (AATD)
Sep 2028
Est. completion
NAGlioma
PrOton Pulsed reduCed dOse Rate Radiotherapy for Recurrent CNS maligNancies Trial
May 2029
Est. completion
P1T-Cell Acute Lymphoblastic Leukemia/Lymphoma
Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma
Feb 2043
Est. completion
Hemoglobinopathy
A Long-term Follow-up Study in Patients Who Received BEAM-101

Awaiting Results (3)

Trials past primary completion date but still active — data readout may be imminent.

Aug 2026
NA
Clinical Trial of the Safety and Efficacy of IBA Proton Therapy System PROTEUS® PLUS (Shenzhen)
NCT07153094
Aug 2026
NA
Clinical Trial of the Safety and Efficacy of IBA Proton Therapy System PROTEUS® PLUS (Hebei)
NCT07137195
Aug 2026
NA
Clinical Trial of the Safety and Efficacy of IBA Proton Therapy System PROTEUS® PLUS (Sichuan)
NCT07152353

Recent Press Releases

SEC Filings (61)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Nov 3, 202610-QQuarterly reportDocumentIndex
Nov 3, 20268-KMaterial eventDocumentIndex
Aug 14, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Aug 13, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Aug 4, 202610-QQuarterly reportDocumentIndex
Aug 4, 20268-KMaterial eventDocumentIndex
Jun 8, 20268-KMaterial eventDocumentIndex
May 7, 202610-QQuarterly reportDocumentIndex
May 7, 20268-KMaterial eventDocumentIndex
Apr 29, 2026SC 13GPassive 5%+ stakeDocumentIndex
Apr 17, 2026ARSAnnual report to holdersDocumentIndex
Apr 17, 2026DEFA14AProxy / shareholder voteDocumentIndex
Apr 17, 2026DEF 14AProxy / shareholder voteDocumentIndex
Mar 26, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Mar 5, 20268-KMaterial eventDocumentIndex
Feb 24, 2026S-8Employee stock planDocumentIndex
Feb 24, 202610-KAnnual reportDocumentIndex
Feb 24, 20268-KMaterial eventDocumentIndex
Feb 12, 20268-KMaterial eventDocumentIndex
Feb 9, 2026SC 13GPassive 5%+ stakeDocumentIndex
Feb 5, 20268-KMaterial eventDocumentIndex
Feb 5, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Feb 5, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Feb 3, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Jan 12, 20268-KMaterial eventDocumentIndex
Dec 11, 20258-KMaterial eventDocumentIndex
Nov 5, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Nov 4, 202510-QQuarterly reportDocumentIndex
Nov 4, 20258-KMaterial eventDocumentIndex
Aug 7, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Aug 6, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Aug 5, 202510-QQuarterly reportDocumentIndex
Aug 5, 20258-KMaterial eventDocumentIndex
Jul 3, 20258-KMaterial eventDocumentIndex
Jun 6, 20258-KMaterial eventDocumentIndex
May 15, 2025SC 13G/APassive 5%+ stakeDocumentIndex
May 13, 2025SC 13G/APassive 5%+ stakeDocumentIndex
May 6, 202510-QQuarterly reportDocumentIndex
May 6, 20258-KMaterial eventDocumentIndex
Apr 18, 2025ARSAnnual report to holdersDocumentIndex